Definition and Pathology Review: Twenty six cases with histologically confirmed diagnosis of FVPTC with FNA slides in our institution for a period of 5 years between 2009-2013 were included in the study.
RESULTS: Histopathological examination showed FVPTC in 26 cases in our institution for 5 years between 2009--2013 were included in the study.
Clinical Parameters: Table 2 lists the clinical and pathological features according to histologic sub variant of FVPTC of 26 cases that were included in the study.
Pathological Parameters: In preoperative FNA diagnosis, 15 cases were diagnosed as adenomatous goitre, 5 as follicular adenoma, 3 as classical PTC, 2 cases as FVPTC and 1 case suspicious of PTC.
Some of these useful antibodies in the diagnosis of FVPTC include cytokeratin 19 (CK19), Hector Battifora mesothelial 1 (HBME1), CREB-binding protein/p300-interacting transactivator with Asp/Glu-rich C-terminal domain 1 (CITED1), galactoside-binding lectin soluble 3 (Galectin-3), CD57, retinoblastoma (Rb) protein, and p27, among others (31,43-46) (Table).
136) Surprisingly, RAS mutations are found more commonly in FVPTC than in other histologic types of PTC, suggesting that FVPTC might be a separate class of thyroid tumors with overlapping features of both PTC and FTC.
PAX8/PPARG gene rearrangement t(2; 3)(q13; p25) is prevalent in FTC (variably reported in 36%-63% of cases) (134,146) as well as in FVPTC, FA, and a small proportion of Hurthle cell carcinomas.
Abbreviations: CITED1, CREB-binding protein/ p300-interacting transactivator with Asp/Glu-rich C-terminal domain 1; CK19, cytokeratin 19; FA, follicular adenoma; FC, follicular carcinoma; FTUMP, follicular tumor of undetermined malignant potential; FVPTC, follicular variant of papillary thyroid carcinoma; Galectin-3, galactoside-binding lectin soluble 3; HBME1, Hector Battifora mesothelial 1; IMP3, insulin-like growth factor II messenger RNA binding protein 3; PTC, papillary thyroid carcinoma.
In our study, patients who had infiltrative/diffuse FVPTC had a significantly greater frequency (P < .
15) One patient with an encapsulated FVPTC with capsular and vascular invasion had a recurrence in the cervical lymph nodes 2 years after surgery.
Indeed, Zhu et al (11) have shown a low frequency (3%) of rearrangement during transfection (RET/PTC rearrangement) and a high frequency of rat sarcoma viral oncogene homolog (RAS) mutations in FVPTC (43%), very similar to observations with follicular carcinoma.